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Letters to the EditorReply to the Letter to the Editor ‘Acute autochthonous hepatitis
E in western patients with underlying chronic liver disease: A role
for ribavirin?’This is a reply to the Letter to the Editor by Peron et al.
We deeply appreciate the information provided by Peron et al.
[1] about two short reports emanating from France [2] and UK [3]
indicating that Genotype 3 HEV have been implicated in the
cause of Acute on Chronic Liver Failure (ACLF) in 9 out of 10
patients, most of whom (n = 7) had underlying alcoholic cirrhosis.
Indeed, it conﬁrmed our suggestion that, such events might be
occurring in industrialized nations and HEV may be associated
with causing ACLF even in non-endemic developed nation [4].
In these geographical areas, autochthonous Genotype 3 HEV
infections in human are implicated as a zoonotic disease and pigs
have been identiﬁed as the reservoir of Genotype 3 HEV. Interest-
ingly, a national survey of acute hepatitis E in France, which
included 19 centres reported that 47 among 53 autochthonous
HEV (majority Genotype 3) infection documented during the
study period might have been due to contaminated water in
many of them [5]. Further, Peron et al in their letter to editor
[1] stated that 26% (9 out of 35) of acute hepatitis E documented
at their centre had underlying chronic liver disease, most of
whom were alcoholic (7 out of 9) [unpublished observation]. This
observation may indicate that, patients with underlying chronic
liver disease may be more prone to contract acute HEV infection
which we have documented and reported [6]. As mentioned ear-
lier, the source of HEV infection may be from water and not nec-
essarily due to only zoonotic transmission, as documented in
France [5]. Therefore, Genotype 3 may also be transmitted
through contaminated water and may cause severe liver disease,
particularly in those with underlying alcoholic liver disease; it
thus needs to be conﬁrmed by prospective evaluation whether
contaminated water is the source of such infection causing ACLF.
However, after diagnostic assays for HEV became available,
prospective studies including large number of patients with acute
liver failure (ALF) from developed nation [7,8] did not report HEV1324 Journal of Hepatology 201as an etiological agent. Furthermore, reviews on HEV in high
income countries [9] and case series of acute HEV infection from
France [10] and UK [11] also did not identify it as an etiological
agent of ALF and ACLF. For this reason, we stated that HEV Geno-
type 3 and 4 (documented as the cause of autochthonous HEV
infection) probably cause more benign disease than the Genotype
1 and 2 HEV infections [4]. The information provided by Peron
et al. [1] may therefore indicate that HEV genotype 3 is associated
with the causation of liver failure (i.e. ACLF) in individuals with
pre-existing liver disease (particularly alcoholic liver disease)
and ALF. Although such infection may be infrequent, prospective
studies in ALF, particularly in France and UK, are needed to estab-
lish HEV genotype 3 as an etiological agent of ALF in these geo-
graphical areas.
We also agree with the authors of the letter to editor that the
initial promise of Ribavirin as an antiviral agent against HEV
infection needs prospective evaluation in a well designed study
with a large number of patients with active viremia.
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2002;137:947–954.Effect of treatment with polyuns
diet-induced
To the Editor:
We read with great interest an article recently published in the
Journal of Hepatology [1]. In this study Miyoshi et al. demon-
strate that hepatic over-expression of the hepatitis C virus
(HCV) core protein is able to induce lipid metabolism dysfunc-
tion and fatty liver accumulation in HepG2 cells. In this context,
HCV core protein might directly or indirectly interfere with the
cellular components of hepatocytes, which ultimately contribute
to the onset of steatosis. The authors discuss that one hypothesis
of the direct steatogenic effect of HCV core protein could be
ascribed to the ability of the viral protein to interfere with mito-
chondrial function resulting in the accumulation of NADH. Inter-
estingly, Vial et al., in another recent article published in this
Journal, demonstrate that the impairment of NADH oxidation
to NAD, with consequent NADH accumulation, is a characteristic
ﬁgure of mitochondrial dysfunction occurring in fatty liver due
to high fat diet (HFD) in rats [2]. Furthermore, Miyoshi et al.
[1] demonstrate that, in HepG2 cells, HCV core protein expres-
sion inﬂuences the nature of fatty acids rather than their quan-
tity. These same effects on fatty acid composition are seen in
hepatocytes from HFD rats [2]. Data from these two studies rep-
resent another relevant demonstration of numerous similarities
between fatty liver by HCV, and non-alcoholic fatty liver disease.
Besides fatty liver, chronic hepatitis C resembles NAFLD in
numerous aspects, such as insulin resistance, and oxidative
stress in the liver. Therefore, HCV infection needs to be viewed
not only as a chronic liver disease but also as a metabolic dis-
ease, opening up a novel way to the molecular understanding
of the pathogenesis of chronic hepatitis C, as a virus-associated
fatty liver [3].
Finally, Miyoshi et al. [1] demonstrate that the treatment with
exogenous polyunsaturated fatty acids (PUFAs) reverts the HCV
core protein-associated changes in fatty acid metabolism. Dietary
PUFAs, which are well established negative regulators of hepatic
lipogenesis, are able to alleviate liver inﬂammation and reduce
fat content in steatotic livers [4]. Recently, we demonstrate that
docosahexaenoic acid (DHA) treatment in children with NAFLD
reduces the levels of plasma triglycerides, and improves insulin
resistance and ultrasonographic features of fatty liver [5]. DHA
might downregulate hepatic triglyceride accumulation by
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decreasing transcriptional activity of sterol regulatory element
binding protein-1 (SREBP-1), and inducing fatty acid catabolism
by activating the peroxisome proliferator-activated receptors
(PPARs) [6]. Since Miyoshi et al. suggest that HCV core protein
may induce hepatic triglyceride accumulation by SREBP-1 activa-
tion and consequent desaturase activation, it is probable that
DHA supplementation may be an efﬁcient therapy also to pre-
vent/treat fatty liver associated with HCV infection.
Finally, since insulin resistance is a common metabolic risk of
NAFLD and chronic hepatitis C, we believe DHA might signiﬁ-
cantly reduce hepatic triglyceride content, ameliorating insulin
sensitivity and other metabolic features that associate NAFLD to
HCV infection. These types of treatments, for their almost com-
plete absence of adverse effects, might be suitable for both adults
and children.
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